7351 patients with T2D and CKD treated with an ACE-inhibitor or an ARB at the maximum dose; UACR 30–300 mg/g and an eGFR 25–90 mL/min/1.73 m2 or UACR 300–5000 mg/g and an eGFR>60 mL/min/1.73 m2; and serum K+ <4.8 mmol/L. This evidence concerns the gene ACE and chronic kidney disease.